Generalized Myasthenia Gravis Symptom Severity Reduced Through Ravulizumab Treatment
The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.
John Vissing, MD, DMSci
In a recent post-hoc analysis from the phase 3 CHAMPION MG study (NCT03920293) presented at the 9th Congress of the European Academy of Neurology, held July 1-4, in Budapest, Hungary, ravulizumab (Ultomiris; AstraZeneca) showed higher benefit in reducing symptom severity compared with placebo in patients generalized myasthenia gravis (gMG) at week 26.1
Approved in April 2022 by the FDA using supportive data from CHAMPION-MG, ravulizumab is a terminal compliment C5 inhibitor for adults who are anti-acetylcholine receptor (AChR) antibody positive. Among 175 patients with gMG, 160 had score-shift data at week 26. Overall, in comparison with placebo, investigators observed a greater number of ravulizumab-treated patients who achieved improved scores in at least 7 of the 8 Myasthenia Gravis–Activities of Daily Living (MG-ADL) items and completed resolution.
Led by author John Vissing, MD, DMSci, professor of neurology, Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, in Copenhagen, Denmark, the post-hoc analysis investigated changes in impairment severity for the 8 MG-ADL items. Impairment, assessed through MG-ADL, was scored between 0-3, with higher scores indicating more severe impairment. Proportions of patients who improved in MG-ADL item scores during the randomized control period were analyzed in the post-hoc analysis.
Patients with an MG-ADL score of 3 in the ravulizumab-treated group were reduced from after 26 weeks in those with eyelid droop (23.1% to 14.1%) and double vision (11.5% and 10.3%). In contrast, the placebo-treated group, observed increases from baseline to week 26 for both eyelid droop (20.7% to 24.4%) and double vision (6.1% to 12.2%).
In a similar recent post-hoc analysis on CHAMPION MG, findings showed ravulizumab significantly improves ocular and respiratory muscle domains. These findings were presented at the 2023 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 19-22, in Dallas, Texas.2 Led by Tahseen Mozaffar, MD, FAAN, director, UC Irvine-MDA ALS and Neuromuscular Center, director, Division of Neuromuscular Diseases, Neurology School of Medicine, the post-hoc analysis aimed to calculate least-square mean changes in MG-ADL, the primary end point, and Quantitative Myasthenia Gravis (QMG) total scores, in 4 separate muscle domains (ocular, bulbar, limb, and respiratory) as a percentage of the respective maximum domain scores.
In the double-blind trial, patients received on study drug received body weight-based doses of 2400 to 3000 mg induction on day 1, then 3000 to 3600 mg every 8 weeks on day 15, or placebo. In 175 enrolled individuals with MG, least-square mean MG-ADL score changes at week 26, expressed as a percentage of the maximum domain score, showed greater improvements for ravulizumab vs placebo in ocular (-14.6% vs -3.2%; P = .0028) and respiratory domains (-10.3% vs -4.2%; P = .0484). Outcomes on bulbar (-12.7% vs 8.0%; P = .0603) were also similar, favoring ravulizumab.
Results from the original trial were published in the New England Journal of Medicine and presented at the 2022 MDA Clinical and Scientific Conference. After 26 weeks of treatment, findings showed statistically significant improvements on the primary end point of MG-ADL total score in ravulizumab-treated patients vs those on placebo (-3.1% vs -1.4%; P <.001).3
Change in QMG total scores, a secondary end point in CHAMPION MG, showed statistically significant improvements following ravulizumab treatment compared with placebo (P <.001). The least squares estimate of the mean QMG change was –2.8 (95% CI, –3.7 to –1.9) in the ravulizumab group and –0.8 (95% CI, –1.7 to 0.1) in the placebo group (P <.001). QMG total scores improved by 5 points or more in a significantly greater proportion of ravulizumab-treated patients than of those receiving placebo (30.0% vs 11.3%; P = .005).
The therapy was also proven to be safe, as demonstrated by a similar proportion of experienced adverse events (AEs) or AEs related to the study drug between each group. There were no notable differences in the types of AEs, with the most frequent event being headache, experienced by 16 patients (19%) in the ravulizumab group and 23 (26%) in the placebo group. Serious AEs were reported in 23% and 16% in the ravulizumab and placebo groups, respectively, the most frequent of which were related to worsening of MG and COVID-19. Two serious AEs (dysphasia and tendonitis) in 2 ravulizumab-treated patients and 4 (cellulitis [2 cases], herpes zoster infection, and infusion-related reaction) serious AEs occurred in the placebo group and were considered treatment-related.
Months after it received FDA approval for MG, published data showed that the C5 compliment inhibitor had a significant ability to reduce relapses in patients with neuromyelitis optica spectrum disorder (NMOSD). The trial, named CHAMPION-NMOSD (NCT04201262), included 58 patients on a weight-based intravenous loading dose of ravulizumab (2400-3000 mg) on day 1, followed by weight-based maintenance doses (3000-3600 mg) on day 15 and once every 8 weeks thereafter. Ravulizumab binds to the same complement component 5 epitope as eculizumab (Soliris; Alexion), a previously approved therapy for NMOSD, and thus, for ethical reasons, investigators used individuals from the placebo arm (n = 47) of the PREVENT study (NCT01892345).4
The primary end point of time to first adjudicated on-trial relapse was met in the ravulizumab arm, as zero relapses were observed over 84.01 patient-years (PY) of treatment. In comparison, there were 20 adjudicated relapses in the placebo arms over 46.93 PY of treatment, representing a 98.6% relapse risk reduction (RRR) with ravulizumab. At 48 weeks, 100% of the patients on ravulizumab were relapse free compared with 63% of those on placebo.
Click here for more coverage of 2023 EAN.
